drugset
drugset / Trial / NCT03471130

Definitive QT Study With MT-8554

NCT03471130 ↗

Phase 1 Completed 48 enrolled Tanabe Pharma America, Inc.
RandomizedParallel-groupTriple-blindOther

Summary

This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF) from Baseline in healthy adult subjects

Timeline

Start
2018-04-23
Primary completion
2018-10-19
Completion
2018-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule — Oral

Indications

No indication recorded.